National Institute for Public Health and the Environment (RIVM), A. van Leeuwenhoeklaan 9, 3720 BA Bilthoven, The Netherlands.
Environ Pollut. 2014 Feb;185:266-70. doi: 10.1016/j.envpol.2013.11.006. Epub 2013 Dec 3.
Demonstrating chemical-induced adverse effects, endocrine mechanisms/modes of action (MOAs) and their causal link is needed for regulatory identification of endocrine disrupting chemicals (EDCs). This paper addresses critical issues over MOAs and their causal link to changes in endpoints. Vitellogenin (VTG), secondary sex characteristics (SSC), and sex ratio (also an apical endpoint) are indicative of chemicals interfering with EAS (estrogen, androgen and steroidogenesis) pathways. These biomarkers, however, can be changed by non-EAS chemicals, systemic toxicity and the stress response. Examples are shown that proving causal link between MOAs and changes in endpoints may be difficult for regulatory identification of EDCs. The paper concludes that both in vitro and in vivo data are needed to define MOAs for regulatory identification of EDCs. Further development of guidance documents for data interpretation and for defining the level of evidence is needed for regulatory identification of EDCs.
为了对内分泌干扰物(EDCs)进行监管识别,需要证明化学物质引起的不良反应、内分泌机制/作用模式(MOA)及其因果关系。本文针对 MOA 及其与终点变化的因果关系这两个关键问题进行了探讨。卵黄蛋白原(VTG)、次级性征(SSC)和性别比例(也是一个顶端终点)是指示化学物质干扰雌激素(E)、雄激素(A)和类固醇生成(S)途径的指标。然而,这些生物标志物也可能会受到非 EAS 化学物质、全身毒性和应激反应的影响而发生变化。本文举例说明了证明 MOA 与终点变化之间的因果关系对于 EDCs 的监管识别可能具有一定难度。本文得出的结论是,需要结合体外和体内数据来确定 EDCs 的监管识别 MOA。此外,还需要进一步制定数据解释和确定证据水平的指导文件,以用于 EDCs 的监管识别。